In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 4 days of free consultation

 

Haemodynamic effects of heart rate lowering in patients admitted for acute heart failure: to save energy by improving effectiveness

Session Poster Session 2

Speaker Andrea Mortara

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Pharmacotherapy
  • Session type : Poster Session
  • FP Number : P1089

Authors : J Rossi (Monza,IT), S Mazzetti (Monza,IT), R Abete (Monza,IT), D Margonato (Monza,IT), M Chioffi (Monza,IT), C Vecchio (Saronno,IT), C Cavalotti (Milan,IT), G Malerba (Varese,IT), A Ciro' (Monza,IT), P Delfino (Monza,IT), A Mortara (Monza,IT)

15 views

Authors:
J Rossi1 , S Mazzetti1 , R Abete1 , D Margonato1 , M Chioffi1 , C Vecchio2 , C Cavalotti3 , G Malerba4 , A Ciro'5 , P Delfino1 , A Mortara1 , 1Polyclinic of Monza, Cardiovascular department - Monza - Italy , 2Saronno General Hospital , Cardiologia - Saronno - Italy , 3Niguarda Ca' Granda Hospital, Cardiologia - Milan - Italy , 4Di Circolo Hospital, Cardiologia - Varese - Italy , 5San Gerardo Hospital, Cardiologia - Monza - Italy ,

Citation:

Background: Heart rate (HR) is a parameter with prognostic value for patients presenting with heart failure (HF) and sinus rhythm in both acute and chronic setting. In patients admitted for acute decompensation, HR could be a compensatory mechanism but also contribute to worsening HF, and indication to drugs which improve HR control is unclear. We analyzed the hemodynamic effect of early administration of ivabradine combined with usual care, 48-72hrs after hospital admission for HF in patients with sinus rhythm and HR >75 bpm. 
Methods and results: Non-invasive hemodynamic parameter (stroke volume, SV, cardiac output, CO, Systemic Vascular Resistance, SVI) were obtained by the Niccomo Device (Medis, Germany) through a bioimpedence technique. Measurements with this device have been shown to be accurate, highly reproducible and sensitivity to normal hemodynamic changes. In this ongoing study, the first 16 acute HF patients enrolled had the following clinical characteristics: mean age 69±16, 31% females, ischemic aetiology 31%, hypertensive 25%, idiopathic 44%, LVEF 39±20%, BNP 1348±1198 pg/mL. Despite clinical stabilization of the patient, after 48-72 hrs from admission, HR was persistently elevated (79,5± 8,5 bpm) and Ivabradine 5 mg bid was started on-top of standard care (beta blockers 62,5 %, diuretics 81,25%, ACE i 62,5%, ARB 12,5%, MRA 56,25%). Measurement were made at the baseline (48-72hrs from admission), after 24-48-72 hrs from starting Ivabradine and at the time of discharge. Treatment with ivabradine was well tolerated in all patients. HR was progressively reduced from 79,5 ± 8,4bpm to 64,2 ±10,1 bpm at hospital discharge, p<0.01. We observed a significant hemodynamic improvement by HR control with an increase of stroke volume (baseline 74,4±9,4 ml vs 85,49±16,4 ml at discharge, p 0,017), and only a minimal reduction of cardiac output (baseline 6,6 ±0,7 L/min vs 5,32 ±1 L/min at discharge, P=ns). All other measures of heart work were also significantly affected by reducing HR.
In conclusion: The strategy of the early administration of ivabradine, during a decompensated episode of HF to control HR on top of usual care including beta-blockers, is feasible and safe. The effect of lowering HR may save energy without affecting cardiac output as confirmed by the significant increase of stroke .



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are